Cureseq is a technology company.
Cureseq has raised $700K across 1 funding round.
Cureseq has raised $700K in total across 1 funding round.
CureSeq is a Brisbane, California-based oncogenomics company developing precision medicine platforms using next-generation sequencing (NGS) to identify cancer and disease-causing mutations from patient biopsy samples.[1][2][3][4] It builds products like the NextDay Seq-Pan Cancer HotSpot Panel kit and Mobile Genome Express (MGE) software, serving clinical labs, research facilities, and oncology professionals by solving the problem of slow, expensive NGS analysis—offering faster turnaround (e.g., 15-minute gDNA applications, three-day commitments), affordability, and automated workflows from sequencer to clinical reports.[2][3][4][6] This enables rapid mutation detection in targeted cancer panels, boosting efficiency in CLIA-certified labs and increasing NGS adoption in oncology.[6]
CureSeq emerged from innovations in rapid NGS for oncology, with early products like the NextDay Seq-Pan Cancer HotSpot Panel kit (a 25-gene targeted panel for hotspot mutations) and MGE, a mobile genetic analysis controller for smartphones that automates data flow from sequencing to reports.[6] Key figures include DMJ and IJK, equity holders and consultants who validated tools against references like COSMIC database mutations, as noted in a 2017 PLOS ONE paper demonstrating its use on Acrometrix Oncology controls.[6] The company gained early traction through biotech investments, including a Seed round from Biao He of Tsingyuan Ventures, highlighting its appeal in life sciences.[7] Pivotal moments include commitments to ultra-fast results, positioning it as a disruptor in oncogenomics.[1][3]
CureSeq rides the precision oncology wave, where NGS demand surges due to personalized cancer treatments and falling sequencing costs, amplified by market forces like rising cancer incidence and regulatory pushes for faster diagnostics.[1][3] Its timing aligns with NGS maturation—post-2017 validations enabling CLIA lab integration amid AI-driven bioinformatics trends—making it a key enabler for real-time mutation profiling that influences treatment decisions and drug development ecosystems.[6] By accelerating biopsy-to-insight pipelines, it bolsters the startup ecosystem through investor interest (e.g., Tsingyuan Ventures) and supports broader adoption in life sciences, potentially shaping competitive landscapes against slower incumbents.[7]
CureSeq's momentum in rapid, affordable oncogenomics positions it for expansion into larger panels, AI-enhanced variant calling, or partnerships with sequencer makers amid booming spatial transcriptomics and single-cell NGS trends.[5][6] Evolving regulations favoring precision medicine and biotech funding could amplify its influence, potentially leading to acquisitions or scaled clinical deployments. As an early investor darling, its trajectory ties back to revolutionizing cancer care through speed—watch for integrations with emerging tools like those from Curio Biosciences to dominate oncology sequencing.[5][7]
Cureseq has raised $700K in total across 1 funding round.
Cureseq's investors include ENIAC Ventures, Biao He, Michael Jin, Foothill Ventures (formerly Tsingyuan Ventures), TEEC Angel Fund, TSVC Capital, VU Venture Partners, John M. Mueller.
Cureseq has raised $700K across 1 funding round. Most recently, it raised $700K Seed in July 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2014 | $700K Seed | ENIAC Ventures, Biao He, Michael Jin, Foothill Ventures (formerly Tsingyuan Ventures), TEEC Angel Fund, TSVC Capital, VU Venture Partners, John M. Mueller |